Perceptive Advisors - Q4 2020 holdings

$9.32 Billion is the total value of Perceptive Advisors's 139 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .

 Value Shares↓ Weighting
BBIO  BRIDGEBIO PHARMA INC$476,883,000
+89.5%
6,706,2680.0%5.12%
+39.3%
 RETROPHIN INCnote 2.500% 9/1$442,521,000
+13.4%
45,000,0000.0%4.75%
-16.6%
 COLLEGIUM PHARMACEUTICAL INCnote 2.625% 2/1$173,250,000
+5.8%
17,500,0000.0%1.86%
-22.3%
 NEVRO CORPnote 2.750% 4/0$165,420,000
+16.6%
9,000,0000.0%1.78%
-14.3%
OM  OUTSET MED INC$161,870,000
+13.7%
2,847,8220.0%1.74%
-16.5%
VBIV  VBI VACCINES INC$151,366,000
-3.8%
55,042,4650.0%1.62%
-29.3%
ATNX  ATHENEX INC$149,669,000
-7.2%
13,532,4670.0%1.61%
-31.8%
ATHA  ATHIRA PHARMA INC$106,682,000
+85.5%
3,114,8050.0%1.14%
+36.5%
RLAY  RELAY THERAPEUTICS INC$96,810,000
-2.4%
2,329,4070.0%1.04%
-28.2%
EIDX  EIDOS THERAPEUTICS INC$90,385,000
+160.4%
686,9220.0%0.97%
+91.3%
ALBO  ALBIREO PHARMA INC$88,529,000
+12.4%
2,360,1390.0%0.95%
-17.4%
QTNT  QUOTIENT LTD$84,406,000
+1.4%
16,200,8180.0%0.91%
-25.5%
KDMN  KADMON HLDGS INC$65,202,000
+5.9%
15,711,3340.0%0.70%
-22.1%
IMVT  IMMUNOVANT INC$64,666,000
+31.3%
1,400,0000.0%0.69%
-3.5%
ZNTL  ZENTALIS PHARMACEUTICALS INC$54,537,000
+58.9%
1,050,0030.0%0.58%
+16.8%
CRNX  CRINETICS PHARMACEUTICALS IN$51,634,000
-10.0%
3,659,3810.0%0.55%
-33.8%
CMPS  COMPASS PATHWAYS PLCsponsored ads$49,898,000
+36.5%
1,047,4040.0%0.54%
+0.2%
AGRX  AGILE THERAPEUTICS INC$45,690,000
-5.6%
15,919,9250.0%0.49%
-30.7%
FMTX  FORMA THERAPEUTICS HLDGS INC$43,625,000
-30.0%
1,250,0000.0%0.47%
-48.6%
ALDX  ALDEYRA THERAPEUTICS INC$43,118,000
-7.4%
6,285,4580.0%0.46%
-31.9%
STOK  STOKE THERAPEUTICS INC$41,616,000
+84.9%
671,9780.0%0.45%
+35.9%
COLL  COLLEGIUM PHARMACEUTICAL INC$41,223,000
-3.8%
2,058,0680.0%0.44%
-29.4%
VRCA  VERRICA PHARMACEUTICALS INC$39,254,000
+48.7%
3,410,4120.0%0.42%
+9.4%
LYRA  LYRA THERAPEUTICS INC$36,737,000
+2.0%
3,222,5610.0%0.39%
-25.1%
VYNE  VYNE THERAPEUTICS INC$36,145,000
-4.8%
22,876,4100.0%0.39%
-30.0%
ADMA  ADMA BIOLOGICS INC$32,340,000
-18.4%
16,584,8020.0%0.35%
-40.1%
RNA  AVIDITY BIOSCIENCES INC$31,538,000
-9.3%
1,235,8180.0%0.34%
-33.5%
ALLO  ALLOGENE THERAPEUTICS INC$28,869,000
-33.1%
1,143,7900.0%0.31%
-50.8%
XBI  SPDR SER TRput$28,156,000
+26.3%
200,0000.0%0.30%
-7.1%
CNCE  CONCERT PHARMACEUTICALS INC$27,184,000
+28.7%
2,150,6410.0%0.29%
-5.2%
IMTX  IMMATICS N.V$26,975,000
+1.7%
2,500,0000.0%0.29%
-25.3%
FUSN  FUSION PHARMACEUTICALS INC$26,273,000
-2.2%
2,235,9830.0%0.28%
-28.1%
PCVX  VAXCYTE INC$22,585,000
-46.2%
850,0000.0%0.24%
-60.5%
GERN  GERON CORP$21,404,000
-8.6%
13,461,5380.0%0.23%
-32.7%
RACA  THERAPEUTICS ACQUISITION COR$20,880,000
-3.2%
1,500,0000.0%0.22%
-28.9%
AMRS  AMYRIS INC$20,583,000
+140.2%
3,333,3320.0%0.22%
+76.8%
VRNA  VERONA PHARMA PLCsponsored ads$20,222,000
+12.2%
2,888,8890.0%0.22%
-17.5%
WVE  WAVE LIFE SCIENCES LTD$19,675,000
-7.3%
2,500,0000.0%0.21%
-31.9%
LPTX  LEAP THERAPEUTICS INC$19,072,000
+13.6%
8,476,4960.0%0.20%
-16.3%
DRNA  DICERNA PHARMACEUTICALS INC$17,624,000
+22.5%
800,0000.0%0.19%
-10.0%
CTMX  CYTOMX THERAPEUTICS INC$16,880,000
-1.5%
2,577,0430.0%0.18%
-27.6%
MORF  MORPHIC HLDG INC$16,339,000
+22.7%
487,0000.0%0.18%
-9.8%
LGVWU  LONGVIEW ACQUISITION CORPunit 99/99/9999$15,155,000
+113.3%
700,0000.0%0.16%
+56.7%
TARA  PROTARA THERAPEUTICS INC$14,733,000
+43.8%
608,5440.0%0.16%
+5.3%
PPH  VANECK VECTORS ETF TRput$13,294,000
+6.9%
200,0000.0%0.14%
-21.4%
TSHA  TAYSHA GENE THERAPIES INC$12,485,000
+18.5%
470,4400.0%0.13%
-13.0%
TCRR  TCR2 THERAPEUTICS INC$12,372,000
+52.2%
400,0000.0%0.13%
+11.8%
SCPEU  SC HEALTH CORPunit 99/99/9999$10,990,000
+3.7%
1,000,0000.0%0.12%
-23.9%
VRAY  VIEWRAY INC$9,366,000
+9.1%
2,451,7480.0%0.10%
-19.2%
RVMD  REVOLUTION MEDICINES INC$8,877,000
+13.8%
224,2240.0%0.10%
-16.7%
PSTX  POSEIDA THERAPEUTICS INC$8,642,000
+23.7%
787,7450.0%0.09%
-8.8%
DYN  DYNE THERAPEUTICS INC$8,400,000
+4.0%
400,0000.0%0.09%
-23.7%
HSAQ  HEALTH SCIENCES ACQ CORP 2$5,765,000
+16.5%
450,0000.0%0.06%
-13.9%
BCTG  BCTG ACQUISITION CORP$5,720,000
+10.4%
500,0000.0%0.06%
-19.7%
DFHTU  DEERFIELD HEALTHCARE TECH ACunit 07/16/2025$4,500,000
+41.1%
300,0000.0%0.05%
+2.1%
MOTS  MOTUS GI HLDGS INC$3,906,000
-3.0%
4,210,5420.0%0.04%
-28.8%
BNR  BURNING ROCK BIOTECH LTDsponsored ads$3,465,000
-7.9%
150,0000.0%0.04%
-32.7%
GRTX  GALERA THERAPEUTICS INC$3,325,000
+13.2%
325,0000.0%0.04%
-16.3%
ADAP  ADAPTIMMUNE THERAPEUTICS PLCsponds adr$2,156,000
-32.5%
400,0000.0%0.02%
-51.1%
EIGR  EIGER BIOPHARMACEUTICALS INC$1,719,000
+51.1%
139,8900.0%0.02%
+5.9%
RACE  FERRARI N V$1,423,000
+24.7%
6,2000.0%0.02%
-11.8%
SRRA  SIERRA ONCOLOGY INC$1,068,000
+50.2%
66,6550.0%0.01%
+10.0%
LEGN  LEGEND BIOTECH CORPsponsored ads$704,000
-8.8%
25,0000.0%0.01%
-27.3%
OTLKW  OUTLOOK THERAPEUTICS INC*w exp 02/18/202$93,000
+72.2%
420,8750.0%0.00%0.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings